Miguel Patricio and Albert Bourla lead very different corporate stories, yet people search for them side by side more often than you might expect. One spent his career building beer and packaged food brands and later chaired Kraft Heinz. The other is a veterinarian turned Pfizer CEO who guided the company through the COVID-19 vaccine rollout and is now steering it through a post-pandemic reset.
This guide answers the questions readers actually ask about Miguel Patricio and Albert Bourla: how much they are worth, what they did at Kraft Heinz and Pfizer, how their leadership styles compare, and what is publicly known about Bourla’s family, background and pay. Where a number is an estimate, we say so.
Quick answers
- Miguel Patricio is a Portuguese born marketing executive and former Kraft Heinz CEO. He now sits on the Kraft Heinz board as a non-employee director.
- Albert Bourla is the Chairman and CEO of Pfizer. He has been CEO since January 2019.
- Patricio’s net worth is commonly estimated at about $30 million to $38 million, mostly in Kraft Heinz shares.
- Bourla earned about $27.6 million in total compensation for 2025, and his base salary is roughly $1.8 million.
- Pfizer has no single owner. Institutions such as Vanguard, BlackRock and State Street hold roughly two thirds of the shares.
Who Are Miguel Patricio and Albert Bourla?
Miguel Patricio is a veteran consumer goods marketer who ran Kraft Heinz from 2019 to 2023 and chaired its board afterward. Albert Bourla is the Greek born chief executive of Pfizer, one of the largest pharmaceutical companies in the world. Both rose through multinational companies, both moved into the chair role after leading as CEO, and both have faced intense investor scrutiny.
Miguel Patricio at a Glance
Patricio was born in Portugal around 1966 or 1967, which makes him about 59 or 60 today. He earned an undergraduate degree at the Getulio Vargas Foundation in Brazil, a path that tied him early to the Brazilian business network behind Ambev and later AB InBev.
| Detail | Information |
| Nationality | Portuguese born, long career in Brazil and the United States |
| Known for | Former CEO and former Chair of Kraft Heinz |
| Current role | Non-employee director at Kraft Heinz; listed as an AB InBev board member from April 2026 by MarketScreener |
| Kraft Heinz CEO tenure | Mid 2019 to December 2023 |
| Chair tenure | Chair from May 2022; Executive Chair from September 2025 until January 1, 2026 |
| Estimated net worth | About $30 million to $38 million (varies by tracker) |
How much is Miguel Patricio worth? Most public estimates tie his wealth to Kraft Heinz stock. MarketScreener valued his known holding of about 1.29 million shares at roughly $30 million as of June 2026. GuruFocus put the same position near $33 million. Another tracker, Quiver Quantitative, lists a minimum net worth of $38.4 million as of September 2026.
Why the gap? Filings show part of his stake sits in family trusts, including a revocable trust and a grantor retained annuity trust, so trackers count different pools of shares. He also sold 250,000 shares in December 2025 at about $24.80 each, which raised roughly $6 million.
These figures exclude cash and assets not disclosed in SEC filings, so treat them as a floor.
Albert Bourla at a Glance
Albert Bourla was born on October 21, 1961, in Thessaloniki, Greece. He holds a veterinary degree and a doctorate in the biotechnology of reproduction from Aristotle University of Thessaloniki. He joined Pfizer in 1993 in its Animal Health business.
| Detail | Information |
| Nationality | Greek by birth, widely described as Greek American; lives in New York |
| Known for | Leading Pfizer and the Pfizer-BioNTech COVID-19 vaccine effort |
| Current role | Chairman and CEO of Pfizer (NYSE: PFE) |
| CEO since | January 2019 |
| Chairman since | January 2020 |
| 2025 total compensation | About $27.6 million |
| Estimated net worth | Public estimates range from about $17 million to $300 million; filings support at least about $28 million in Pfizer related holdings |
How much is Albert Bourla worth? Online estimates are all over the map. Some sites say $17 million, others $50 million, $100 million or even $200 million to $300 million. Most do not explain their math.
A more grounded approach uses his SEC filings. Simply Wall St reports that he directly owns about 0.007% of Pfizer, worth roughly $9.9 million. A Form 4 filed on July 1, 2026, shows he also holds about 772,979 phantom stock units in a deferred compensation plan. At the $24.08 unit price listed in that filing, those units are worth about $18.6 million.
Adding the two gives roughly $28 million in disclosed Pfizer related holdings. That is our own arithmetic, and it excludes unvested awards, taxes and any assets outside Pfizer. It is a documented floor, not a full net worth.
Miguel Patricio’s Career and Leadership at Kraft Heinz
Patricio took over Kraft Heinz in 2019 with a clear mandate: restart organic growth through stronger brands rather than deeper cost cuts. He left the CEO job at the end of 2023, stayed as chair, and spent his final stretch helping plan a company breakup that his successors later paused.
Miguel Patricio’s Professional Background
Patricio built his reputation in marketing long before he ran a company. His career, according to Kraft Heinz and market data records, followed this path:
- Johnson & Johnson (1989 to 1995): Global marketing director.
- The Coca-Cola Company (1996 to 1997): Global marketing director.
- Philip Morris International (1997 to 1999): Vice president of marketing.
- Ambev (1999 to 2004): Chief marketing officer of the Brazilian brewer, a predecessor of AB InBev.
- AB InBev (2005 to 2019): Zone president for North America, then Asia Pacific, then global chief marketing officer from 2012 to 2018.
His Asia Pacific years stand out. AB InBev’s revenue in the region grew from about $1 billion in 2008 to $2.7 billion in 2012, making it the number one beer company in China, according to the announcement of his Kraft Heinz appointment.
That record explains why Kraft Heinz’s owners wanted a brand builder after years of heavy cost control.
His Leadership at Kraft Heinz
Patricio became CEO in mid 2019, replacing Bernardo Hees. He said at the time that his focus would be accelerating organic growth and strengthening the brands in the portfolio. The company, formed by the 2015 merger of Kraft Foods and H.J. Heinz, had struggled with write-downs and slow sales.
Key moments in his time at the top:
- 2019 to 2023: Served as CEO, shifting attention toward marketing, innovation and brand investment.
- May 2022: Became Chair of the Board, succeeding Alexandre Behring.
- January 2024: Handed the CEO role to Carlos Abrams-Rivera, who served until the end of 2025.
- September 2025: Became Executive Chair as the board announced a plan to split Kraft Heinz into two public companies, one focused on groceries and the other on sauces and spreads.
- December 2025: Kraft Heinz named Steve Cahillane CEO, effective January 1, 2026. Patricio stepped down as Executive Chair and left his employment but stayed on the board. John T. Cahill became Chair.
The split drew criticism. Warren Buffett told CNBC the original merger “did not turn out to be a brilliant idea,” and he doubted a breakup would fix the problems. In February 2026, Cahillane paused the separation work, said many challenges were “fixable and within our control,” and committed about $600 million to marketing, sales and R&D.
That pause says a lot about his legacy: a respected brand builder who inherited a hard portfolio and left before his strategy was finished. Kraft Heinz reported a net loss of nearly $6 billion for 2025 after more than $6 billion in goodwill impairments.
Albert Bourla’s Career and Leadership at Pfizer
Albert Bourla has spent more than three decades at Pfizer and has been its CEO since January 2019. His tenure includes the fastest vaccine development effort in history, a sharp revenue swing after the pandemic, and a large rebuild around oncology and obesity medicines.
Albert Bourla’s Rise to Pfizer CEO
Bourla’s climb at Pfizer was steady and global. Per Pfizer’s 2026 proxy statement, his key roles were:
- 1993: Joined Pfizer, working in the Animal Health business.
- 2010 to 2013: President and General Manager of the Established Products Business Unit.
- 2014: Took responsibility for Vaccines, Oncology and Consumer Healthcare.
- 2016 to 2017: Group President of Pfizer Innovative Health.
- 2018: Chief Operating Officer.
- January 2019: Became CEO, succeeding Ian Read.
- January 2020: Became Chairman of the Board.
He left Greece at 34 to take on a larger Pfizer role and has since lived and worked in several countries. Institutional Investor ranked him America’s top pharmaceutical CEO in 2020.
His Leadership During the COVID-19 Era
Bourla became a global name when Pfizer and BioNTech developed one of the first authorized COVID-19 vaccines. Pfizer said in November 2020 that early data showed efficacy above 90%, and the shot became the backbone of vaccination campaigns worldwide.
The windfall did not last. Pfizer misjudged how quickly demand for its COVID products would fall in 2023. The company then:
- Bought Seagen for about $43 billion to build an oncology franchise built on antibody drug conjugates.
- Ran a cost savings program of about $4 billion, which it reported as delivered in 2024.
- Reorganized its R&D teams.
- Faced a challenge from an activist investor in 2024.
Bourla also drew attention for his personal choices during the rollout. He publicly postponed an Israel trip in March 2021 because he had received only one of two doses and did not want to cut the line. He received his second dose on March 10, 2021. Fact checkers later rated viral claims that he avoided vaccination as mostly false.
Albert Bourla and Pfizer in 2026
In 2026, Pfizer is telling investors it is in a “defining period.” The company reaffirmed guidance in February and May, then raised its full-year revenue guidance by $500 million at the midpoint when it reported second-quarter results on August 4, 2026.
What stands out in the 2026 picture:
- Growth products: Launched and acquired products grew 22% operationally in the first quarter and 18% in the second.
- Pipeline: Pfizer expects about 20 key pivotal study starts in 2026, with oncology and obesity as lead priorities.
- Obesity push: The acquisition of Metsera was a core part of Pfizer’s 2025 strategy to compete in next-generation weight management drugs.
- Oncology deals: A global in-licensing agreement with 3SBio added to the pipeline, and a transaction with Innovent Biologics is expected to reduce 2026 adjusted EPS by about $0.10.
- Policy: Pfizer reached a voluntary agreement with the U.S. government on drug pricing in 2025.
- Efficiency: The company expanded its productivity initiatives and expects about $5.7 billion in net cost savings through 2026 from its main program.
- Leadership team: Cecile Guegan was named incoming interim CFO.
In 2025, Pfizer said its medicines and vaccines reached more than 448 million patients.
Miguel Patricio vs. Albert Bourla: How Their Leadership Careers Compare
The two executives share a pattern of long tenures at global companies and high stakes turnarounds, but they come from opposite ends of the business world. Patricio is a brand and marketing specialist in consumer goods. Bourla is a scientist turned operator in pharmaceuticals.
| Factor | Miguel Patricio | Albert Bourla |
| Industry | Packaged food and beverages | Pharmaceuticals and vaccines |
| Background | Marketing | Veterinary science and operations |
| Top role | Former CEO and Chair, Kraft Heinz | Chairman and CEO, Pfizer |
| CEO start | 2019 | 2019 |
| Current status | Non-employee director | Active CEO and Chair |
| Defining moment | Brand focused turnaround and planned split | COVID-19 vaccine and post-pandemic reset |
Different Areas of Expertise
Patricio’s strength is consumer insight: how products are positioned, priced and sold, in a world driven by shelf space and household habits.
Bourla’s strength is science and regulated operations. Pfizer’s results depend on clinical data, approvals and government pricing talks, and a single trial readout can move the stock.
Global Experience and Corporate Leadership
Both men are truly international. Patricio worked across Latin America, North America and Asia Pacific for AB InBev. Bourla has lived in multiple countries since leaving Greece and ran Pfizer’s established products, vaccines and oncology units before taking the top job.
Both also held the chair role alongside or after the CEO job, which gives influence over strategy but invites governance questions from shareholders.
Transformation and Long-Term Strategy
Patricio’s biggest strategic bet was structural: separate Kraft Heinz into two focused companies. It was paused within weeks of his successor taking over. Bourla’s biggest bets are portfolio moves: Seagen, Metsera, new licensing deals and a push into obesity and cancer drugs, all built to offset the fall in COVID revenue and upcoming patent expirations.
The key difference is timing. Bourla is still in the seat and judged on delivery through the end of the decade. Patricio’s decisions are now being tested, and in part reversed, by new leadership.
Albert Bourla’s Family, Nationality, and Personal Background
Albert Bourla is Greek by birth, Sephardic Jewish by heritage, and a New York resident with a wife and two adult children. He keeps his family life private, so reliable details are limited.
What Is Albert Bourla’s Nationality?
Albert Bourla is a Greek national who was born in Thessaloniki and later built his career in the United States. Media outlets usually call him a Greek American executive. He lives with his wife in Scarsdale, New York, and returns to Thessaloniki most summers, where family still lives.
His family history is closely tied to the city. Thessaloniki once had a large Sephardic Jewish community that traced back to the Spanish expulsion of 1492. Bourla has said that about 50,000 Jews lived there when Germany invaded Greece and that only about 2,000 survived. His parents were among them.
How Many Children Does Albert Bourla Have?
Albert Bourla has two children, a daughter and a son. He is married to Myriam Alchanati Bourla. The family stays out of the spotlight, and Bourla rarely shares details about his children publicly.
He also has a sister, Seli, who lives in Thessaloniki.
Who Is Albert Bourla’s Daughter?
Albert Bourla has not publicly shared his daughter’s name or details about her life, and no credible primary source confirms them. Some low quality websites publish names and personal stories about his children, but these are not backed by interviews, filings or reputable reporting, so we do not repeat them.
Is Albert Bourla a Zionist?
There is no reliable public evidence that Albert Bourla has described himself as a Zionist, and no primary source in our research shows him taking part in political Zionist advocacy. Zionism is a political movement, while Jewish identity is a religious, cultural and ethnic one. The two are not the same, and one cannot be assumed from the other.
What the record does show is business and heritage connections to Israel and the Jewish community:
- Bourla planned a trip to Israel in early 2021, then postponed it because he was waiting for his second vaccine dose.
- He spoke at an annual Holocaust commemoration hosted by Sephardic Heritage International in January 2021.
- He received the 2022 Genesis Prize, a $1 million honor, for his role in the vaccine effort.
Be careful with this topic. Many online posts that ask about Bourla’s religion or politics lean on conspiracy theories about Jewish executives, which are antisemitic and not supported by facts. If you want to judge his decisions, look at Pfizer’s filings, pricing choices and clinical results instead.
What Religion Is Albert Bourla?
Albert Bourla is Jewish and comes from a Sephardic family. He has publicly discussed his heritage and his parents’ survival of the Holocaust in Thessaloniki. His religion is not a business factor in how Pfizer operates, and it should not be treated as one.
Albert Bourla’s Salary and Compensation
Albert Bourla’s total pay for 2025 was about $27.6 million, and his base salary is around $1.8 million. The rest comes from a bonus and long term equity tied to performance, according to Pfizer’s proxy statement and trade press coverage.
| Year | Total compensation | Notes |
| 2020 | About $21 million | Vaccine development year |
| 2022 | About $33 million | Peak COVID sales year; his highest to date |
| 2024 | $24.6 million | 14% increase from 2023 |
| 2025 | About $27.6 million | Second highest of his tenure |
Details for 2025:
- Base salary: About $1.8 million, or roughly 6.5% of total pay.
- Bonus: $5.4 million, which the compensation committee tied to strong operating results.
- Performance based share: Pfizer says 92% of his compensation is performance based.
- Other compensation: About $1.9 million, including $610,650 for security.
- Reasons for the rise: The board cited the Metsera acquisition, the U.S. pricing agreement and the cost savings program.
For context, Johnson & Johnson’s Joaquin Duato earned about $32.8 million in 2025 and Eli Lilly’s David Ricks about $36.7 million, according to Fierce Pharma, so Bourla’s package sits below the top of the group.
Pfizer’s 2025 proxy statement also reported that his 2024 pay was 269 times that of the median employee.
Who Owns Pfizer Today?
Pfizer is a publicly traded company on the New York Stock Exchange under the ticker PFE, so no single person or family owns it. Institutional investors hold about 66% to 68% of the shares, the general public holds about 31% to 34%, and insiders own only around 0.03%.
Based on recent ownership data from Simply Wall St and TIKR:
- Vanguard: About 9% across its fund entities, historically the largest holder.
- BlackRock: About 8.7%.
- State Street Global Advisors: About 5.3%.
- Geode Capital Management: About 2.3%.
- Norges Bank Investment Management: About 1.3%.
The top 25 holders together own about 41% of the company. Because most of those are index funds, ownership is spread out and stable, and no investor controls the board. Bourla’s own stake is small compared with the institutional base, which is normal for a company of Pfizer’s size.
Ownership percentages change each quarter, so check the latest SEC filings.
Why Miguel Patricio and Albert Bourla Are Being Discussed Together
There is no known business partnership or shared board seat linking the two. The pairing comes mostly from search behavior and shared themes, not from a single news event.
Here is why the names appear together:
- Net worth searches: Readers who look up one CEO’s wealth often compare it with another prominent executive’s.
- CEO turned chair: Both held the top job in 2019 and later moved into or kept a chair role.
- Turnaround stories: Each led a company through a major reset, one in food and one in pharma.
- Board and governance headlines: Leadership changes at Kraft Heinz in late 2025 and Pfizer’s 2026 proxy and earnings news pulled both names into the news cycle.
- Investor curiosity: Both stocks have traded around $24 to $26 a share in 2026, which keeps valuation debates alive.
If you see claims that the two have teamed up or joined each other’s boards, check the source. We found no filing or company announcement that supports such a link.
Frequently Asked Questions
What is Miguel Patricio’s net worth?
Estimates range from about $30 million to $38 million, based largely on his Kraft Heinz shares and trust holdings.
What is Albert Bourla’s net worth?
Online estimates vary widely, but SEC filings show at least about $28 million in Pfizer related holdings, so the real figure is higher.
Is Miguel Patricio still the CEO of Kraft Heinz?
No. He stepped down as CEO in December 2023 and left the Executive Chair role on January 1, 2026, but remains a board member.
Who is the CEO of Kraft Heinz now?
Steve Cahillane has been Kraft Heinz CEO since January 1, 2026.
Who is the CEO of Pfizer?
Albert Bourla is Chairman and CEO of Pfizer and has led the company since January 2019.
How much does Albert Bourla make?
He earned about $27.6 million in total compensation for 2025, including a salary of roughly $1.8 million.
What is Albert Bourla’s nationality?
He is Greek by birth and is widely described as Greek American.
How many children does Albert Bourla have?
He has two children, a daughter and a son.
Who is Albert Bourla’s wife?
His wife is Myriam Alchanati Bourla, and the couple lives in Scarsdale, New York.
Is Albert Bourla Jewish?
Yes. He comes from a Sephardic Jewish family in Thessaloniki, Greece.
Is Albert Bourla a Zionist?
There is no reliable public evidence that he has described himself that way, and Jewish identity does not equal a political position.
Who owns Pfizer?
Pfizer is publicly traded, with institutions like Vanguard, BlackRock and State Street holding most shares.
Was Albert Bourla arrested?
No. Pfizer confirmed to Full Fact that arrest claims were false and traced them to a satirical site.
Did Miguel Patricio join Pfizer’s board?
We found no evidence of that. Market data lists him as a Kraft Heinz director and an AB InBev board member from April 2026.
Why did Kraft Heinz pause its split?
New CEO Steve Cahillane said in February 2026 that returning to profitable growth came first and that many problems were fixable.
Conclusion
Miguel Patricio and Albert Bourla share a rare milestone: both took over major global companies in 2019. Patricio used his marketing background to try to revive Kraft Heinz, then helped set up a split that his successor chose to pause. Bourla turned a vaccine breakthrough into a broader reset at Pfizer, and in 2026 he is still making the case that obesity and oncology will drive its next growth phase.
On money, the best documented numbers point to Patricio at roughly $30 million to $38 million, and to Bourla with at least $28 million in disclosed Pfizer holdings plus pay near $27.6 million a year. Beware of any site that gives a single exact net worth without showing its work.
For the most accurate view, follow primary sources such as SEC Form 4 and proxy filings, where changes in pay, ownership and leadership show up first.
Daniel Wilson is the admin of Meaning Lexi, a website focused on the meanings of words, names, phrases, and symbols. He is dedicated to providing clear, accurate, and easy-to-understand content for readers.
